- Home
- FTHM vs VTVT Comparison
FTHM vs VTVT Comparison
Compare FTHM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- VTVT
- Stock Information
- Founded
- FTHM 2010
- VTVT 2015
- Country
- FTHM United States
- VTVT United States
- Employees
- FTHM N/A
- VTVT N/A
- Industry
- FTHM Real Estate
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- VTVT Health Care
- Exchange
- FTHM Nasdaq
- VTVT Nasdaq
- Market Cap
- FTHM 54.7M
- VTVT 54.4M
- IPO Year
- FTHM 2020
- VTVT 2015
- Fundamental
- Price
- FTHM $1.25
- VTVT $25.50
- Analyst Decision
- FTHM Strong Buy
- VTVT Strong Buy
- Analyst Count
- FTHM 1
- VTVT 2
- Target Price
- FTHM $2.50
- VTVT $35.50
- AVG Volume (30 Days)
- FTHM 209.8K
- VTVT 3.8K
- Earning Date
- FTHM 11-11-2025
- VTVT 11-06-2025
- Dividend Yield
- FTHM N/A
- VTVT N/A
- EPS Growth
- FTHM N/A
- VTVT N/A
- EPS
- FTHM N/A
- VTVT N/A
- Revenue
- FTHM $390,032,000.00
- VTVT $17,000.00
- Revenue This Year
- FTHM $25.22
- VTVT N/A
- Revenue Next Year
- FTHM $16.19
- VTVT N/A
- P/E Ratio
- FTHM N/A
- VTVT N/A
- Revenue Growth
- FTHM 19.16
- VTVT N/A
- 52 Week Low
- FTHM $0.65
- VTVT $12.62
- 52 Week High
- FTHM $3.37
- VTVT $27.00
- Technical
- Relative Strength Index (RSI)
- FTHM 34.87
- VTVT 73.00
- Support Level
- FTHM $1.54
- VTVT $22.45
- Resistance Level
- FTHM $1.84
- VTVT $25.30
- Average True Range (ATR)
- FTHM 0.13
- VTVT 1.40
- MACD
- FTHM -0.03
- VTVT 0.39
- Stochastic Oscillator
- FTHM 15.94
- VTVT 80.56
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.